Prophylactic treatment of esophageal varices before bleeding.

Hepatogastroenterology

Service d'Hépato-gastro-entérologie, C.H.U. Purpan, Toulouse, France.

Published: December 1990

After years of effort, the treatment of an episode of bleeding from a ruptured varix remains unsatisfactory, as does prophylaxis of rebleeding. As a consequence it was logical to try to prevent bleeding before the first hemorrhage has occurred (primary prophylaxis). Shunt surgery proved to be useful in terms of bleeding rate, but side effects and operative risk made this method inapplicable for prophylaxis. Endoscopic sclerotherapy was efficient in terms of bleeding rate, but doubts about its efficacy in improving survival, together with difficulties in performing repeated endoscopies over the long term, have limited its use in primary prophylaxis. Beta-blockers have proved useful for preventing bleeding and, in some studies, for improving survival. Further studies are still necessary to accurately identify the suitable target population, the method of follow-up and the duration of treatment. Although some groups have started using beta-blockers for prophylaxis before bleeding on a routine basis, others consider this treatment only for prospective randomized trials.

Download full-text PDF

Source

Publication Analysis

Top Keywords

primary prophylaxis
8
terms bleeding
8
bleeding rate
8
improving survival
8
bleeding
7
prophylaxis
5
prophylactic treatment
4
treatment esophageal
4
esophageal varices
4
varices bleeding
4

Similar Publications

Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics.

View Article and Find Full Text PDF

Background/objectives: Urinary tract infections (UTI) represent a highly frequent and debilitating disease. Immunoactive prophylaxis, such as the polyvalent bacterial whole-cell-based sublingual vaccine MV140, have been developed to avoid antibiotic use. However, the effectiveness of this tool in the Portuguese population is still unknown.

View Article and Find Full Text PDF

Objectives: This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT) (PCV13i) in infants.

Methods: A total of 1200 infants were randomly assigned to either the experimental PCV13i group or the control PCV13 group in a 1:1 ratio. Each group received a three-dose series of the vaccine at 2, 4, and 6 months of age, followed by a booster dose at 12-15 months.

View Article and Find Full Text PDF

Evaluation of Integrated Child Health Days as a Catch-Up Strategy for Immunization in Three Districts in Uganda.

Vaccines (Basel)

November 2024

U.S. Centers for Disease Control and Prevention, Global Immunization Division, Global Health Center, Atlanta, GA 30329, USA.

Uganda's Integrated Child Health Day (ICHD) initiative aims to improve children's access to vaccinations. Although widely used as a catch-up vaccination strategy, the effectiveness of the ICHD program in increasing immunization coverage, especially among vulnerable populations, has not been recently evaluated. This study assessed the reach and uptake of ICHD for immunizations in Uganda.

View Article and Find Full Text PDF

Background/objective: This study aimed to investigate the efficacy of oral probiotic supplementation in preventing vulvovaginal infections (VVIs) in pregnant women, specifically focusing on abnormal vaginal flora (AVF), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC).

Methods: A multicenter-prospective-randomized, double-blind, placebo-controlled trial was conducted during 2016-2019. Women with normal vaginal flora (Nugent score < 4 and no candida) were divided into a research group, receiving 2 capsules/day of oral probiotic formula containing , , , , , and , or a control group, receiving a placebo until delivery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!